Cynata Therapeutics awarded grant to progress stem cell therapies for coronary artery disease

Cynata Therapeutics Ltd (ASX:CYP) has been awarded a Federal Government Innovations Connections grant to advance development of therapies based on its Cymerus technology platform for the treatment of coronary artery disease (CAD).

CAD, which is the narrowing or blockage of the arteries in the heart, causes the majority of heart attacks and about one-third of all deaths in people over the age of 35 in developed countries.

The Innovations Connections grant of $50,000 is supported by the Australian Governments Department of Industry Innovation and Science.

These funds will be used to support the continuation of research at the University of NSW in Sydney under the leadership of Associate Professor Kristopher Kilian, ARC future fellow at the UNSW School of Chemistry and School of Materials Science and Engineering.

“Look forward to generating new data”

Cynata's chief operating officer Dr Kilian Kelly said: “We are very pleased to receive this non-dilutive funding which enables us to further our research into the development of customised MSCs that address CAD before a heart attack occurs.

“Associate Professor Kristopher Kilian and his team have already demonstrated the potential value of this approach and we now look forward to generating further data in support of a future clinical trial.”

This further research leads on from a collaborative project with this group which started in 2018 and identified optimal cell culture matrices to stimulate the growth of new Read More – Source

Related Articles

Back to top button